03966nam 22006614a 450 991087680740332120200520144314.01-280-27526-X97866102752670-470-02142-X0-470-02141-1(CKB)1000000000357241(EBL)232685(SSID)ssj0000170472(PQKBManifestationID)11171219(PQKBTitleCode)TC0000170472(PQKBWorkID)10223946(PQKB)10515328(MiAaPQ)EBC232685(OCoLC)85820613(EXLCZ)99100000000035724120041130d2005 uy 0engur|n|---|||||txtccrThe hERG cardial potassium channel structure, function, and long QT syndrome /[editors, Derek J. Chadwick, James Goode]New York J. Wiley20051 online resource (309 p.)Novartis Foundation symposium ;266Based on a symposium.0-470-02140-3 Includes bibliographical references and indexes.THE hERG CARDIAC POTASSIUM CHANNEL: STRUCTURE, FUNCTION AND LONG QT SYNDROME; Contents; Participants; Chair's introduction; Gating and assembly of heteromeric hERG1a/1b channels underlying I(Kr) in the heart; Discussion; Structure-function studies of the outer mouth and voltage sensor domain of hERG; Discussion; General discussion I; Voltage sensor movement in the hERGK(+) channel; Discussion; hERG channel trafficking; Discussion; Dynamic control of hERG/I(Kr) by PKA-mediated interactions with 14-3-3; Discussion; General discussion IIDoes hERG coassemble with a b subunit? Evidence for roles of MinK and MiRP1Discussion; hERG block, QT liability and sudden cardiac death; Discussion; Structural determinants for high-affinity block of hERG potassium channels; Discussion; Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs; Discussion; In silico modelling-pharmacophores and hERG channel models; Discussion; The long QTsyndrome: a clinical counterpart of HERG mutations; Discussion; Cellular mechanisms of Torsade de Pointes; DiscussionExpression and role of hERG channels in cancer cellsDiscussion; TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability); Discussion; Drug-induced QT interval prolongation: regulatory guidance and perspectives on hERG channel studies; Discussion; Closing remarks; Index of contributors; Subject indexThis book draws together contributions from basic, pharmaceutical and clinical sciences aimed at a better understanding of the structure and function of hERG and the molecular basis for compound binding. It features regulatory authority perspectives on preferred preclinical test systems and includes topics on hERG channel gating, regulation of functional expression, pharmacological properties of hERG/IKr channels, drug-induced long QT syndrome and preclinical evaluation and regulatory recommendations for assessing QT prolongation risks. Better understanding of the role of the hERG channeNovartis Foundation symposium ;266.Potassium channelsCongressesLong QT syndromeCongressesHeartPhysiologyCongressesHeartPathophysiologyCongressesPotassium channelsLong QT syndromeHeartPhysiologyHeartPathophysiology612.1/7Chadwick Derek91632Goode Jamie283336Novartis Foundation.MiAaPQMiAaPQMiAaPQBOOK9910876807403321The hERG cardial potassium channel4204539UNINA